About Allogene Therapeutics, Inc.
https://www.allogene.comAllogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL.
CEO
David D. Chang
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 80
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Citigroup
Buy
Truist Securities
Buy
HC Wainwright & Co.
Buy
Canaccord Genuity
Buy
Citizens Capital Markets
Market Outperform
Oppenheimer
Outperform
Grade Summary
Showing Top 6 of 11
Price Target
Institutional Ownership
PFIZER INC
Shares:22.03M
Value:$37.45M
TPG GROUP HOLDINGS (SBS) ADVISORS, INC.
Shares:18.72M
Value:$31.82M
TPG GP A, LLC
Shares:18.72M
Value:$31.82M
Summary
Showing Top 3 of 203
About Allogene Therapeutics, Inc.
https://www.allogene.comAllogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $13.74M ▼ | $-41.4M ▲ | 0% | $-0.19 ▲ | $-37.96M ▲ |
| Q2-2025 | $0 | $56.82M ▼ | $-50.94M ▲ | 0% | $-0.23 ▲ | $-47.57M ▲ |
| Q1-2025 | $0 | $62.09M ▲ | $-59.73M ▲ | 0% | $-0.28 | $-56.48M ▼ |
| Q4-2024 | $0 | $57.26M ▼ | $-59.94M ▲ | 0% | $-0.28 ▲ | $-56.18M ▲ |
| Q3-2024 | $0 | $71.77M | $-66.29M | 0% | $-0.32 | $-62.99M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $252.19M ▼ | $439.77M ▼ | $124.44M ▼ | $315.33M ▼ |
| Q2-2025 | $273.12M ▼ | $470.59M ▼ | $126.03M ▲ | $344.56M ▼ |
| Q1-2025 | $280.04M ▼ | $507.98M ▼ | $122.59M ▼ | $385.39M ▼ |
| Q4-2024 | $292.48M ▲ | $548.71M ▼ | $126.53M ▲ | $422.18M ▼ |
| Q3-2024 | $291.56M | $589.12M | $125.37M | $463.75M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-41.4M ▲ | $-29.69M ▲ | $11.94M ▼ | $3.24M ▼ | $-14.52M ▼ | $-29.93M ▲ |
| Q2-2025 | $-50.94M ▲ | $-39.03M ▲ | $43.84M ▲ | $5.07M ▼ | $9.88M ▲ | $-39.07M ▲ |
| Q1-2025 | $-59.73M ▲ | $-52.93M ▼ | $6.18M ▼ | $13.99M ▲ | $-32.76M ▼ | $-53.03M ▼ |
| Q4-2024 | $-59.94M ▲ | $-36.7M ▲ | $54.93M ▲ | $5.74M ▲ | $23.98M ▲ | $-36.95M ▲ |
| Q3-2024 | $-66.29M | $-44.12M | $-75.99M | $679K | $-119.43M | $-44.54M |
Revenue by Products
| Product | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|
 License | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
David D. Chang
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 80
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Citigroup
Buy
Truist Securities
Buy
HC Wainwright & Co.
Buy
Canaccord Genuity
Buy
Citizens Capital Markets
Market Outperform
Oppenheimer
Outperform
Grade Summary
Showing Top 6 of 11
Price Target
Institutional Ownership
PFIZER INC
Shares:22.03M
Value:$37.45M
TPG GROUP HOLDINGS (SBS) ADVISORS, INC.
Shares:18.72M
Value:$31.82M
TPG GP A, LLC
Shares:18.72M
Value:$31.82M
Summary
Showing Top 3 of 203